0001415889-24-027905.txt : 20241127 0001415889-24-027905.hdr.sgml : 20241127 20241127200006 ACCESSION NUMBER: 0001415889-24-027905 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241125 FILED AS OF DATE: 20241127 DATE AS OF CHANGE: 20241127 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Campbell David Alan CENTRAL INDEX KEY: 0001864158 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40475 FILM NUMBER: 241512893 MAIL ADDRESS: STREET 1: C/O JANUX THERAPEUTICS, INC. STREET 2: 11099 N. TORREY PINES ROAD, SUITE 290 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Janux Therapeutics, Inc. CENTRAL INDEX KEY: 0001817713 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822289112 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10955 VISTA SORRENTO PARKWAY STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 751-4493 MAIL ADDRESS: STREET 1: 10955 VISTA SORRENTO PARKWAY STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 form4-11272024_081102.xml X0508 4 2024-11-25 0001817713 Janux Therapeutics, Inc. JANX 0001864158 Campbell David Alan C/O JANUX THERAPEUTICS, INC. 10955 VISTA SORRENTO PARKWAY, SUITE 200 SAN DIEGO CA 92130 true true false false President and CEO 1 Common Stock 2024-11-25 4 S 0 18281 51.4322 D 263773 D Common Stock 2024-11-25 4 S 0 6719 52.0385 D 257054 D The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024. The weighted average sale price for the transaction reported was $51.4322 and the range of prices were between $50.89 and $51.885. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $52.0385 and the range of prices were between $51.89 and $52.385. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. /s/ James Pennington, Attorney-in-Fact 2024-11-27